KRAS, NRAS,BRAF mutation testing Doctors Abroad — Page 2

Dr. Viola Fox is the Chief Physician at the Clinic for Oncology in Solingen. She is a leading expert in drug therapy for tumors in Germany and Europe. Dr. Fox holds a qualification in specialist genetics and conducts molecular biology research. She treats complex cases at a certified interdisciplinary cancer center.

• Member of the American Association for Cancer Research.
• Specializes in immunotherapy, targeted therapy, and molecular diagnostics.
• Treats hematological diseases, including lymphoma, leukemia, and myeloma.
• Works at Städtisches Klinikum Solingen, a clinic ranked among the top in Germany.

Dr. Irfan Cicin is a Professor of Medical Oncology at İstinye University Liv Hospital Topkapı. He specializes in treating complex cancers, including glioblastoma, lung cancer, and pancreatic tumors. He serves as a professor at the Trakya University Faculty of Medicine. Dr. Cicin previously served as a physician in the Turkish Air Force.

• Performs systemic therapies such as immunotherapy, chemotherapy, and hormone therapy.
• Treats a wide range of conditions including gynecologic, orthopedic, and neuro-oncology cases.
• Expert in HIPEC and chemoembolization for liver and abdominal malignancies.
• Works at a 300-bed university hospital with 33 medical departments.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at Liv Hospital Topkapı. He specializes in treating colon, breast, gastric, and lung cancers. He previously served as the Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital. Dr. Atci is a member of the American Society of Clinical Oncology (ASCO).

• Author of 19 peer-reviewed papers on gastrointestinal, thoracic, and endocrine cancers.
• Published studies on survival outcomes for stage IIB colon cancer in the Journal of Chemotherapy.
• Researches prognostic biomarkers using PET/CT scans and metabolic tumor volume.
• Treats complex oncological cases at the university-affiliated İstinye University clinic.

Dr. Mustafa Serkan Alemdar is a clinical oncologist at Medical Park Antalya Hospital Complex. He specializes in treating complex solid tumors and blood cancers. Dr. Alemdar completed his medical degree and oncology fellowship at Akdeniz University. He is an active member of the Turkish Society of Medical Oncology.

• Treats a wide range of cancers including breast, lung, and prostate.
• Expert in hematology-oncology for conditions like leukemia, myeloma, and lymphoma.
• Performs systemic therapies such as chemotherapy, immunotherapy, and targeted biological therapy.
• Works at a facility that houses specialized oncology-bone marrow units and LINAC technology.

Dr. Hasan Mutlu is a medical oncologist at Medical Park Antalya Hospital Complex. He specializes in immunotherapy, targeted cancer therapies, and genetic research in cancer treatment. Dr. Mutlu received his medical degree from Hacettepe University. He holds the title of Professor of Medicine. Dr. Mutlu focuses on organ tumor diagnosis and chemotherapy.

• Specializes in both medical and pediatric oncology cases.
• Treats complex conditions including neuroblastoma, Wilms tumor, and Ewing's sarcoma.
• Performs biological therapies and stays active in next-generation genetic research.
• Works at the Mediterranean region’s largest private hospital with PET-CT and LINAC technology.

Dr. Auala Hubert chairs the Gastrointestinal Cancer Center at Hadassah Medical Center. He uses KRAS, NRAS, and BRAF mutation testing to guide advanced cancer therapies.

• Holds specialist certifications in both medical oncology and radiotherapy
• Performs HIPEC – delivers heated chemotherapy directly into the abdominal cavity
• Member of the Israel Society of Clinical Oncology committee for gastrointestinal cancer
• Uses CyberKnife and Brachytherapy for precise tumor targeting
• Qualified in USMLE standards for medical practice

Dr. Yaacov Lawrence is the Chair of Radiation Oncology at Sheba Medical Center. He specializes in precision radiation therapy and neuro-oncology. Dr. Lawrence pioneered celiac plexus radiosurgery for pancreatic cancer pain management. He holds the FASTRO designation, one of the highest honors in his specialty.

• Leads the Gastrointestinal Cancer Program at Sheba Medical Center.
• Performs stereotactic radiosurgery for brain tumors and nervous system cancers.
• Authored over 280 scientific publications on personalized radiation protocols.
• Completed radiation oncology fellowship training at Thomas Jefferson University.

Dr. Jair Bar is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He specializes in treating advanced non-small cell lung cancer using personalized immunotherapy and targeted treatments. Dr. Bar holds a PhD in Molecular Biology and leads a research lab focused on immunotherapy resistance.

• Chair of the Israel Lung Cancer Group.
• Board-certified in both Medical Oncology and Radiotherapy Oncology.
• Treats patients at Sheba Medical Center, a top-10 globally ranked hospital.
• Uses molecular and genetic profiling to create precise cancer treatment plans.

Prof. Beni Boursi is a gastrointestinal oncology specialist at Sheba Medical Center. He uses KRAS, NRAS, and BRAF mutation testing for targeted therapy planning.

• Trained in oncology at the University of Pennsylvania and MD Anderson Cancer Center
• Academic scholar at the Perelman School of Medicine in the United States
• Published research on drug responses in patients with BRAF V600 mutations
• Member of the Israeli Association of Clinical Oncology and Radiotherapy
• Researches microbiome interactions to improve how patients respond to cancer treatments

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Dr. Zulfu Sertkaya is an associate professor and andrologist at Andro Expertise in Istanbul. He holds the FEBU title from the European Association of Urology. Dr. Sertkaya focuses on male health, sexual function, and aesthetic urological procedures. He treats patients at his clinic and performs surgeries at affiliated hospitals.

• Earned Fellow of the European Board of Urology (FEBU) status.
• Specialize in andrology, male sexual health, and aesthetic urology.
• Performs penile implant surgery and varicocelectomy for infertility.
• Works at a clinic accredited by the Turkish Medical Association.

Dr. Brenda Pastrana is a surgical oncologist at the JCI-accredited Galenia Hospital in Cancún. She specializes in breast, thyroid, and digestive system cancers. Dr. Pastrana is board-certified by CONACEM. She holds a medical degree from the Universidad Autónoma de México.

• Performs mastectomies, liver resections, and complex colon cancer surgeries.
• Treats patients at a facility holding Accreditation Canada Diamond Status.
• Serves as a university teacher at Universidad Anáhuac.
• Member of the Mexican Society of Oncology (SMEO).

Professor Eckhart Weidmann heads the hematology department at Nordwest Clinic. KRAS, NRAS, and BRAF mutation testing helps him determine precise therapy for blood disorders.

• Specializes in treating complex blood cancers and non-Hodgkin lymphoma
• Leads a dedicated department at a major German academic hospital
• Focuses on targeted therapies based on genetic mutation profiles
• Member of the German Society of Hematology and Medical Oncology (DGHO)

Dr. Elnur Sahibov is a specialist in radiation oncology at Emsey Hospital. He provides expertise in oncology services including KRAS, NRAS, and BRAF mutation testing.

• Trained at Marmara University Faculty of Medicine in radiation oncology
• Completed medical specialization between 2012 and 2016
• Graduated from the English-language medical program at Marmara University
• Practices at Emsey Hospital, a private multi-specialty center in Turkey

Dr. Shruti Kate heads the oncology department at HCG Manavata Cancer Centre. She previously served as a consultant at the prestigious Tata Memorial Hospital.

• Specializes in solid tumors and pediatric cancers requiring KRAS, NRAS, and BRAF mutation testing
• Presented lung cancer research at the 2018 World Conference on Lung Cancer in Toronto
• Won a travel award from the International Association for the Study of Lung Cancer
• Member of the American Society of Clinical Oncology and the European Society for Medical Oncology
• Expert in using immunotherapy and metronomic therapy for advanced cancer stages

Dr. Chaitainya Borde has handled more than 30,000 PET scans at HCG Manavata Cancer Centre. This experience supports precise KRAS, NRAS, and BRAF mutation testing for cancer patients.

• Specializes in nuclear medicine – provides detailed imaging for accurate diagnosis
• Expert in all PET-CT scans for tracking cancer growth
• Published medical papers on advanced imaging and therapy
• Experienced in radioiodine and Lu-177 RN therapies for cancer
• Treated 1,000+ thyroid cancer patients using specialized nuclear services

Prof. Dr. Gül Alço is a radiation oncologist with about 27 years of experience. She treats breast, lung, prostate, gastrointestinal, gynecologic, central nervous system, head and neck, soft tissue, and bone cancers with radiotherapy.

Her expertise includes adaptive radiotherapy and radiosurgery. She uses advanced radiation techniques to provide personalized, evidence-based care in a multidisciplinary, patient-centered setting.

Prof. Dr. Abdullah Sakin is a professor of medical oncology. He treats solid tumors, including lung, breast, gastrointestinal, genitourinary, gynecologic, head and neck cancers, and melanoma.

He delivers personalized, evidence-based care. His treatments include chemotherapy, targeted therapy, immunotherapy, hormone therapy, and precision oncology. He has authored more than 200 scientific publications and takes part in international clinical research. This work advances patient-centered cancer care.